TTN (Titin)

PCDS is a cross-cohort robust tool for predicting melanoma prognosis and immunotherapy benefit, reflecting the degree of immunosuppression in the tumor immune microenvironment and myeloid/macrophage-related immunoregulatory features, and provides a basis for individualized risk stratification and potential drug selection. This study provides an in-depth elucidation of the regulatory mechanisms of PCD in the tumor immune microenvironment and offers an important theoretical foundation for personalized treatment decision-making in melanoma patients.

Methods We performed whole exome sequencing (WES), bulk RNAseq, multiplex immunofluorescence (mIF) and chromogenic immunohistochemistry (IHC) on tumor tissue and flow cytometry of the peripheral blood to study longitudinal changes following the combination of avelumab with utomilumab (a 4-1BB agonist) (arm A), PF-04518600 (an OX40 agonist) (arm B), utomilumab and PF-04518600 (arm C) and utomilumab and radiotherapy (arm D) in phase I/II study (NCT03217747). Conclusions Our findings, though limited, highlight genomic differences between histologic subsets and outcome as well as the need for combination strategies that drive the recruitment and/or priming of anti-tumor T cells and address low immune permissive tumor states in patients with advanced solid tumors. Clinical trial registration: This clinical trial was registered on clinicaltrials.gov NCT03217747.

A high tumor mutational burden (>10) is rare in oral cavity squamous cell carcinoma. Further research into the interplay between genetic mutations and patient outcomes is needed.

Urinary titin may serve as a potential marker associated with postoperative complications.

Potential tumor-suppressing properties have been revealed through OBSCN lncRNAs and epigenetic regulation. This review aims to provide a comprehensive overview of obscurin's molecular functions and interactions by discussing the effects of its differential expression and its interactions with binding partners, along with the differences and similarities between vertebrate and invertebrate obscurin.

This is the first reported case of seropositive, overlap irAEs consisting of myocarditis and polyradiculoneuritis. Early immunosuppressive therapy can alleviate irAEs but can also lead to serious complications in frail patients. This underscores the importance of carefully balancing expected therapeutic benefits against potential risks.

This study provides the first systematic characterization of the clinical profile of AChR-Ab+/Titin-Ab+ myasthenia gravis patients in Southwest China. Our findings indicate that dual antibody-positive MG patients are more prone to generalized disease involvement and have a higher susceptibility to thyroid dysfunction.

Our comprehensive genomic characterization of patient-derived LCOs provides valuable insights into the mutational landscape and evolutionary dynamics of lung cancer. These well-annotated organoid models serve as a powerful resource for investigating tumor biology and developing genomically informed therapeutic strategies.

A TRGs-based prognostic model effectively predicts survival in EC and reveals associations with somatic mutations, immune infiltration, and drug sensitivity. Functional validation of PTGES3 further supports its potential as a therapeutic target.

Blocking the DLL4-MCT4 axis stimulated anti-tumor immunity and synergized with anti-PD-1, improving response rates for first-line neoadjuvant therapy in TNBC. Our study revealed intrinsic mechanism by which TTN regulates the tumor immune microenvironment and provided a potential target for immunotherapy in TNBC with TTN inactivation.

Our findings demonstrate that chemotherapy may selectively reduce passenger mutations in mCRC, potentially influencing the persistence of hypermutated subclones. This highlights the potential role of passenger mutation patterns and TMB as biomarkers for treatment response and raises the hypothesis that they could help guide immunotherapy considerations for patients with MSS mCRC.

Holliday junction recognition protein emerges as a significant biomarker in LUAD, consistently associated with poor prognosis across multiple cohorts. Its role in various oncogenic pathways and correlation with advanced disease stages underscore the potential of HJURP as a target for therapeutic intervention and as a marker for prognosis in LUAD.